Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: A randomized, open-label trial

Lutz Fischer, Pavel Trunečka, Bruno Gridelli, Andre Roy, Alessandro Vitale, Andrés Valdivieso, Evaristo Varo, Daniel Seehofer, Stephen Lynch, Didier Samuel, Bo Goran Ericzon, Karim Boudjema, Carmen Karpf, Nasrullah Undre

Research output: Contribution to journalArticle

Abstract

Tacrolimus, a cornerstone immunosuppressant, is available as a twice-daily formulation (tacrolimus bid). A once-daily prolonged-release formulation (tacrolimus qd) has been developed. This 6-week, randomized, phase 2, multicenter, open-label, prospective trial in primary liver transplant recipients investigated and compared the pharmacokinetics (PK) of tacrolimus for qd and bid formulations. All patients received tacrolimus-based immunosuppression (tacrolimus qd, n = 67; bid, n = 62). PK data were available for 77 patients (tacrolimus qd, n = 45; bid, n = 32). Tacrolimus area under the curve (AUC) from 0 to 24 hours (AUC0-24) at equivalent doses was approximately 50% lower for tacrolimus qd than for bid on day 1 (146 versus 264 ng·h/mL, respectively), but by day 14 was comparable between treatments (324 and 287 ng·h/mL, respectively) with higher tacrolimus qd doses. There was a strong correlation between AUC0-24 and concentration at 24 hours for tacrolimus qd and bid (r = 0.92 and r = 0.76, respectively). Furthermore, the relationship between these 2 parameters (ie, the slope of the line) was also similar for the 2 formulations. Efficacy endpoints were comparable for both formulations at 6 weeks with no marked differences in incidence, nature, or severity of adverse events between treatments (although the study was not powered to draw efficacy conclusions). These results suggest that targeting the same trough levels will achieve similar total AUC over 24 hours for both tacrolimus qd and tacrolimus bid in de novo liver transplant recipients.

Original languageEnglish
Pages (from-to)167-177
Number of pages11
JournalLiver Transplantation
Volume17
Issue number2
DOIs
Publication statusPublished - Feb 2011

Fingerprint

Tacrolimus
Liver Transplantation
Pharmacokinetics
Area Under Curve
Liver
Immunosuppressive Agents
Immunosuppression

ASJC Scopus subject areas

  • Surgery
  • Transplantation
  • Hepatology

Cite this

Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation : A randomized, open-label trial. / Fischer, Lutz; Trunečka, Pavel; Gridelli, Bruno; Roy, Andre; Vitale, Alessandro; Valdivieso, Andrés; Varo, Evaristo; Seehofer, Daniel; Lynch, Stephen; Samuel, Didier; Ericzon, Bo Goran; Boudjema, Karim; Karpf, Carmen; Undre, Nasrullah.

In: Liver Transplantation, Vol. 17, No. 2, 02.2011, p. 167-177.

Research output: Contribution to journalArticle

Fischer, L, Trunečka, P, Gridelli, B, Roy, A, Vitale, A, Valdivieso, A, Varo, E, Seehofer, D, Lynch, S, Samuel, D, Ericzon, BG, Boudjema, K, Karpf, C & Undre, N 2011, 'Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: A randomized, open-label trial', Liver Transplantation, vol. 17, no. 2, pp. 167-177. https://doi.org/10.1002/lt.22211
Fischer, Lutz ; Trunečka, Pavel ; Gridelli, Bruno ; Roy, Andre ; Vitale, Alessandro ; Valdivieso, Andrés ; Varo, Evaristo ; Seehofer, Daniel ; Lynch, Stephen ; Samuel, Didier ; Ericzon, Bo Goran ; Boudjema, Karim ; Karpf, Carmen ; Undre, Nasrullah. / Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation : A randomized, open-label trial. In: Liver Transplantation. 2011 ; Vol. 17, No. 2. pp. 167-177.
@article{36a8f6f3fdef4d49851d647c13d02966,
title = "Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: A randomized, open-label trial",
abstract = "Tacrolimus, a cornerstone immunosuppressant, is available as a twice-daily formulation (tacrolimus bid). A once-daily prolonged-release formulation (tacrolimus qd) has been developed. This 6-week, randomized, phase 2, multicenter, open-label, prospective trial in primary liver transplant recipients investigated and compared the pharmacokinetics (PK) of tacrolimus for qd and bid formulations. All patients received tacrolimus-based immunosuppression (tacrolimus qd, n = 67; bid, n = 62). PK data were available for 77 patients (tacrolimus qd, n = 45; bid, n = 32). Tacrolimus area under the curve (AUC) from 0 to 24 hours (AUC0-24) at equivalent doses was approximately 50{\%} lower for tacrolimus qd than for bid on day 1 (146 versus 264 ng·h/mL, respectively), but by day 14 was comparable between treatments (324 and 287 ng·h/mL, respectively) with higher tacrolimus qd doses. There was a strong correlation between AUC0-24 and concentration at 24 hours for tacrolimus qd and bid (r = 0.92 and r = 0.76, respectively). Furthermore, the relationship between these 2 parameters (ie, the slope of the line) was also similar for the 2 formulations. Efficacy endpoints were comparable for both formulations at 6 weeks with no marked differences in incidence, nature, or severity of adverse events between treatments (although the study was not powered to draw efficacy conclusions). These results suggest that targeting the same trough levels will achieve similar total AUC over 24 hours for both tacrolimus qd and tacrolimus bid in de novo liver transplant recipients.",
author = "Lutz Fischer and Pavel Trunečka and Bruno Gridelli and Andre Roy and Alessandro Vitale and Andr{\'e}s Valdivieso and Evaristo Varo and Daniel Seehofer and Stephen Lynch and Didier Samuel and Ericzon, {Bo Goran} and Karim Boudjema and Carmen Karpf and Nasrullah Undre",
year = "2011",
month = "2",
doi = "10.1002/lt.22211",
language = "English",
volume = "17",
pages = "167--177",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation

T2 - A randomized, open-label trial

AU - Fischer, Lutz

AU - Trunečka, Pavel

AU - Gridelli, Bruno

AU - Roy, Andre

AU - Vitale, Alessandro

AU - Valdivieso, Andrés

AU - Varo, Evaristo

AU - Seehofer, Daniel

AU - Lynch, Stephen

AU - Samuel, Didier

AU - Ericzon, Bo Goran

AU - Boudjema, Karim

AU - Karpf, Carmen

AU - Undre, Nasrullah

PY - 2011/2

Y1 - 2011/2

N2 - Tacrolimus, a cornerstone immunosuppressant, is available as a twice-daily formulation (tacrolimus bid). A once-daily prolonged-release formulation (tacrolimus qd) has been developed. This 6-week, randomized, phase 2, multicenter, open-label, prospective trial in primary liver transplant recipients investigated and compared the pharmacokinetics (PK) of tacrolimus for qd and bid formulations. All patients received tacrolimus-based immunosuppression (tacrolimus qd, n = 67; bid, n = 62). PK data were available for 77 patients (tacrolimus qd, n = 45; bid, n = 32). Tacrolimus area under the curve (AUC) from 0 to 24 hours (AUC0-24) at equivalent doses was approximately 50% lower for tacrolimus qd than for bid on day 1 (146 versus 264 ng·h/mL, respectively), but by day 14 was comparable between treatments (324 and 287 ng·h/mL, respectively) with higher tacrolimus qd doses. There was a strong correlation between AUC0-24 and concentration at 24 hours for tacrolimus qd and bid (r = 0.92 and r = 0.76, respectively). Furthermore, the relationship between these 2 parameters (ie, the slope of the line) was also similar for the 2 formulations. Efficacy endpoints were comparable for both formulations at 6 weeks with no marked differences in incidence, nature, or severity of adverse events between treatments (although the study was not powered to draw efficacy conclusions). These results suggest that targeting the same trough levels will achieve similar total AUC over 24 hours for both tacrolimus qd and tacrolimus bid in de novo liver transplant recipients.

AB - Tacrolimus, a cornerstone immunosuppressant, is available as a twice-daily formulation (tacrolimus bid). A once-daily prolonged-release formulation (tacrolimus qd) has been developed. This 6-week, randomized, phase 2, multicenter, open-label, prospective trial in primary liver transplant recipients investigated and compared the pharmacokinetics (PK) of tacrolimus for qd and bid formulations. All patients received tacrolimus-based immunosuppression (tacrolimus qd, n = 67; bid, n = 62). PK data were available for 77 patients (tacrolimus qd, n = 45; bid, n = 32). Tacrolimus area under the curve (AUC) from 0 to 24 hours (AUC0-24) at equivalent doses was approximately 50% lower for tacrolimus qd than for bid on day 1 (146 versus 264 ng·h/mL, respectively), but by day 14 was comparable between treatments (324 and 287 ng·h/mL, respectively) with higher tacrolimus qd doses. There was a strong correlation between AUC0-24 and concentration at 24 hours for tacrolimus qd and bid (r = 0.92 and r = 0.76, respectively). Furthermore, the relationship between these 2 parameters (ie, the slope of the line) was also similar for the 2 formulations. Efficacy endpoints were comparable for both formulations at 6 weeks with no marked differences in incidence, nature, or severity of adverse events between treatments (although the study was not powered to draw efficacy conclusions). These results suggest that targeting the same trough levels will achieve similar total AUC over 24 hours for both tacrolimus qd and tacrolimus bid in de novo liver transplant recipients.

UR - http://www.scopus.com/inward/record.url?scp=79551500191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551500191&partnerID=8YFLogxK

U2 - 10.1002/lt.22211

DO - 10.1002/lt.22211

M3 - Article

C2 - 21280190

AN - SCOPUS:79551500191

VL - 17

SP - 167

EP - 177

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 2

ER -